Rubius Therapeutics Income Tax

Rubius Therapeutics's income tax stands at $54M as of December 2022. That compares with $10M in the prior-year period — up 415.4% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Rubius Therapeutics reported $54M in income tax versus $10M a year earlier — a 415.4% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $10M in the prior-year period — up 415.4% year over year. Sustained growth in income tax can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Rubius Therapeutics's income tax evolved across reporting periods, while the comparison chart places RUBY next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, income tax is commonly used to spot outliers. Rubius Therapeutics's reading of $54M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.